CDP571 data

Celltech (Slough, U.K.) reported Phase II results at the meeting of the American College of Rheumatology in Minneapolis, showing a 40 percent or more reduction in pain scores and reduction of 22-27 percent in swelling of monitored joints associated with the highest dose tested, 10 mg/kg. Both findings were statistically significant.

The 36 patients had failed to respond to at least one existing disease-modifying drug. ...